ArticleFrontiers in immunology2026
CT-derived topological intratumoral heterogeneity predicts major pathological response to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer: a two-center study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop and validate a pretreatment computed tomography (CT)-derived model for predicting major pathological response (MPR) to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer (NSCLC). Methods: This multicenter retrospective study included 287 patients with stage IB-III NSCLC treated with neoadjuvant immunotherapy plus chemotherapy followed by surgery. Patients from Center A formed the training cohort (n = 224), and patients from Center B formed the external validation cohort (n = 63). Two-dimensional (2D) and three-dimensional (3D) intratumoral heterogeneity scores (ITHscores) were derived from venous-phase pretreatment CT using local radiomics, K-means clustering and connected-component topology. Candidate predictors included clinicopathological variables, ITHscores and blood-derived inflammatory indicators. Eight machine-learning algorithms were compared, and the final model was selected using cross-validation and feature ablation. Shapley additive explanations (SHAP) analysis was used to interpret feature contributions. Results: Non-MPR tumors showed significantly higher 2D and 3D ITHscores than MPR tumors in both cohorts (all P < 0.001). CatBoost was selected as the optimal algorithm. SHAP analysis identified 2D ITHscore and 3D ITHscore as the two most influential predictors, with mean absolute SHAP values of 0.403 and 0.326, respectively. The final parsimonious model retained 2D ITHscore, 3D ITHscore and systemic immune-inflammation index. It achieved AUCs of 0.824 in the training cohort and 0.792 in the external validation cohort, outperforming the clinical and ITH-only models. Calibration and decision curve analyses showed acceptable agreement and potential clinical utility. Conclusion: CT-derived topological intratumoral heterogeneity, combined with systemic inflammation, may provide a non-invasive pretreatment biomarker for predicting MPR in resectable NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.